Microfluidics Device Captures and Isolates Slow Growing Gut Bacteria
|
By LabMedica International staff writers Posted on 15 Jul 2014 |

Image: Glass SlipChip for growing microbes, shown next to a US quarter dollar coin (left); fluorescent in situ hybridization image of the target organism (right, top); transmission electron microscopy image of a single cell of the target organism (right, bottom) (Photo courtesy of the California Institute of Technology).
Microbiologists have used a novel "lab-on-a-chip" approach to isolate and cultivate fastidious, slow growing bacteria from the human digestive tract.
The majority of microbes that comprises the human gut biome have not been cultured, due in part to the difficulties of both identifying proper growth conditions and characterizing and isolating each species.
Investigators at the California Institute of Technology (Pasadena, USA) developed a microfluidics-based, genetically targeted approach to overcome these problems. Their "SlipChip" device was constructed from two glass slides, each the size of a credit card, that were etched with tiny grooves that became channels when the grooved surfaces were stacked atop one another. When a sample, such as a mixed assortment of bacterial species from a colonoscopy biopsy, was applied to the device, the interconnected channels of the top chip turned the channels into individual wells, with each well ideally holding a single microbe. Once sequestered in an isolated well, each individual bacterium was able to divide and grow without having to compete for resources with other types of faster-growing microbes.
The beauty of the system was that each well could be divided into two compartments. One compartment was used for DNA sequencing and mapping studies while the other maintained a living example of the microbe for further culture and study.
The investigators validated this approach by cultivating a bacterium from a human cecal biopsy. Genetic mapping of the organism showed that it was a representative of a previously unidentified genus of the Ruminococcaceae family and that its genetic signature was listed among the high-priority group of the [US] National Institutes of Health's Human Microbiome Project’s "Most Wanted" list.
"Although a genomic sequence of the new organism is a useful tool, further studies are needed to learn how this species of microbe is involved in human health," said senior author Dr. Rustem Ismagilov, professor of chemistry and chemical engineering at the California Institute of Technology.
The study was published in the June 25, 2014, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
California Institute of Technology
The majority of microbes that comprises the human gut biome have not been cultured, due in part to the difficulties of both identifying proper growth conditions and characterizing and isolating each species.
Investigators at the California Institute of Technology (Pasadena, USA) developed a microfluidics-based, genetically targeted approach to overcome these problems. Their "SlipChip" device was constructed from two glass slides, each the size of a credit card, that were etched with tiny grooves that became channels when the grooved surfaces were stacked atop one another. When a sample, such as a mixed assortment of bacterial species from a colonoscopy biopsy, was applied to the device, the interconnected channels of the top chip turned the channels into individual wells, with each well ideally holding a single microbe. Once sequestered in an isolated well, each individual bacterium was able to divide and grow without having to compete for resources with other types of faster-growing microbes.
The beauty of the system was that each well could be divided into two compartments. One compartment was used for DNA sequencing and mapping studies while the other maintained a living example of the microbe for further culture and study.
The investigators validated this approach by cultivating a bacterium from a human cecal biopsy. Genetic mapping of the organism showed that it was a representative of a previously unidentified genus of the Ruminococcaceae family and that its genetic signature was listed among the high-priority group of the [US] National Institutes of Health's Human Microbiome Project’s "Most Wanted" list.
"Although a genomic sequence of the new organism is a useful tool, further studies are needed to learn how this species of microbe is involved in human health," said senior author Dr. Rustem Ismagilov, professor of chemistry and chemical engineering at the California Institute of Technology.
The study was published in the June 25, 2014, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
California Institute of Technology
Latest Microbiology News
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








